5-Amino-1MQ Key Research Facts Chemical name: 5-Amino-1-Methylquinolinium (also abbreviated as 5A-1MQ or 5MQ) Target enzyme: Nicotinamide N-Methyltransferase (NNMT) Mechanism: Competitive inhibition of NNMT reduces 1-MNA production, preserves nicotinamide for NAD+ synthesis and SAM for epigenetic methylation Selectivity: High selectivity for NNMT does not inhibit related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes Membrane permeability: High passive and active transport permeability confirmed in PAMPA and Caco-2 cell assays NNMT expression: Upregulated in obese adipose tissue, multiple cancer types, and aged skeletal muscle tissue contexts of primary research interest Downstream targets: NAD+ availability, SIRT1/SIRT3 activity, SAM-dependent epigenetic methylation, lipogenesis, energy expenditure Pre-clinical models: Diet-induced obese (DIO) mice, 3T3-L1 adipocyte cell models, aged mouse skeletal muscle models, HeLa cancer cell lines In vitro cell viability: No impact on cell viability at 10 M concentration in 3T3-L1 pre-adipocytes in published toxicity profiling What Does 5-Amino-1MQ Do in Research

Vision loss and a smooth tongue
Metabolic benefits beyond the scale Weight loss is the headline
In rare cases, particularly with severe megaloblastic anaemia, rapid correction of B12 deficiency can affect potassium distribution in the body
Oral Capsule Protocol Standard Dosing: Dose: 100 to 300 mg per day Frequency: Once or twice daily Timing: With or without food Duration: 8 to 12 weeks Oral dosing requires higher amounts because some of the compound is lost during digestion